ELIGIBILITY (data collected on entry form)
- Adults with significant acute upper or lower gastrointestinal bleeding
- Responsible clinician is substantially uncertain as to the appropriateness of tranexamic acid in a patient

Appropriate CONSENT PROCESS
(ie patient, representative or waiver)
If a waiver is used, consent for continuation in the trial should be sought from the patient or relative as soon as possible after the emergency is over OR the patient regains competence.

RANDOMISE (tranexamic acid or placebo)
Enter form completed

LOADING DOSE over 10 minutes

MAINTENANCE DOSE over 24 hours

If waiver used, obtain consent from patient or representative.
Complete OUTCOME FORM at discharge, death or day 28 whichever is earlier.

All clinically indicated treatment is given in addition to trial enrolment.
Report adverse events as per protocol (up to day 28).